By Jon Hamilton, NPR
Paul knew his young grandson was in danger.
“Out of the corner of my eye I could see this little figure moving,” he says. The figure was heading for a steep flight of stairs.
But what could he do? Paul was sitting down. And after more than a decade of living with Parkinson’s disease, getting out of a chair had become a long and arduous process.
But not on this day.
“Paul jumped up from the chair and ran to my grandson,” says his wife, Rose. (The couple asked to be identified by their first names to protect their medical privacy). “I mean, he just got up like there was nothing and ran to pick up Max.”
Amazing. But it’s also the kind of story that’s become familiar to Peter Strick, professor and chair of neurobiology at the University of Pittsburgh and scientific director of the University of Pittsburgh Brain Institute.
“It was a great example of what people call paradoxical kinesia,” Strick says. “It was a description of just what we are studying.”
Paradoxical kinesia refers to the sudden ability of a person with Parkinson’s to move quickly and fluidly, the way they did before the disease eroded a brain area involved in movement.
The phenomenon is a variation of the placebo effect. But instead of being induced by the belief that a sugar pill is really medicine, it tends to appear in situations that involve stress or a strong emotion.
For Paul, “it was the fear of his grandson falling down the stairs,” says Strick, who learned about the event in an email from Rose.
A treatment that’s “all in your head”
Strick believes the placebo effect deserves more respect than it often gets.
“I love it when people say it’s all in your head, because your brain is in your head,” he says. “There are real biological underpinnings for these kinds of things.”
So Strick has assembled a team of prominent scientists to find the biological underpinnings of paradoxical kinesia. The team hopes what they learn will lead to new treatments for Parkinson’s, which affects nearly one million people in the U.S.
The effort involves several labs at the University of Pittsburgh and one at the University of California, Santa Barbara. It’s being funded by a $12 million grant from the Aligning Science Across Parkinson’s Initiative and implemented by the Michael J. Fox Foundation.
Strick’s collaborators plan to focus on two circuits in the brain that appear to control voluntary movement. One is damaged by Parkinson’s, leading to symptoms including tremor, freezing, and poor balance and coordination.
“Our hypothesis is that there’s another circuit that’s intact, and that this circuit isn’t affected in Parkinson’s disease,” Strick says.
Strick’s team believes this other circuit can be switched on by strong emotions, including positive ones.
“It’s engaged by our sense of reward, by the joy of doing something,” he says.
A placebo with wheels
For at least one Parkinson’s patient, Strick says, that appears to include the joy of riding a bike.
Strick is fascinated by a video made by Dutch neurologists back in 2010.
It begins with a man who has severe Parkinson’s struggling to walk down a hospital corridor. He’s hunched over, shuffling his feet, his hands are trembling. Then it shows the same man, minutes later, effortlessly riding a bike around the hospital parking lot.
Most of Strick’s collaborators at the University of Pittburgh have seen that video, says William Stauffer, a neurobiologist whose lab studies reward and emotion.
“What I find really incredible is that he’s riding the bike and he comes back and he hops off the bike and he freezes,” Stauffer says. “It’s immediate. That’s weird.”
The team believes that for this man, riding the bike was like taking a placebo because it gave him joy. But when the man got off, the joy — and its benefits — disappeared almost instantly.
To Stauffer, this behavior is one more piece of evidence that people with Parkinson’s still do have an intact movement circuit in the brain, a pathway that is only switched on in certain situations.
“If you can somehow isolate the pathway that enables that and turn it on,” Stauffer says, it might offer a new approach to treating Parkinson’s.
A monkey model from a drug gone bad
Parkinson’s gradually kills or disables cells that make dopamine, a chemical messenger associated with both movement and feelings of pleasure, reward, and joy.
The drug L-DOPA can replace dopamine. But its effect tends to wane over time and higher doses can produce side effects, like involuntary movements. Deep brain stimulation can also reduce symptoms like tremor, but requires surgery and carries risks.
So scientists have been searching for ways to improve treatments by studying monkeys, whose brains control movement much the way human brains do.
That research is possible because of something tragic that happened in Northern California, says Rob Turner, whose lab at the University of Pittsburgh studies the brain circuits that allow skillful movement.
In the early 1980s, people who were using a form of heroin began showing up at hospitals with symptoms that looked strikingly similar to Parkinson’s.
“One of the local neurologists, Bill Langston, did the detective work and he discovered that someone had botched a batch of synthetic opioids and made a neurotoxin instead,” Turner says.
This neurotoxin attacks the same brain cells involved in Parkinson’s disease. A little toxin kills a few cells, a lot kills many more — making it possible to mimic the stages of Parkinson’s. That discovery allowed scientists to learn a lot about how the disease damages a human brain, Turner says.
“The other thing about it is that it gave us the ability to produce a monkey model of Parkinson’s remarkably similar to what we see in humans,” he says.
So Turner’s lab will use this monkey model to study how the placebo effect works. To do that, though, they’ll need to induce enough joy in a monkey to switch on the brain circuit that restores normal movement.
The team is still thinking about how to do that. But Turner says just the prospect of getting a fruit juice reward makes a monkey happy. So how about the prospect of a really special treat, like a tropic smoothie?
“Not just the normal, small-size tropic smoothie,” Turner says. “The monkey’s going to get the ‘yes, nice work!’ kind of reward.
The prospect of a smoothie, of monkey joy, will act as the placebo in this experiment. With luck, it will cause a monkey’s brain to switch on the circuit that temporarily allows normal movement.
But because this is occurring in a monkey, in the lab, scientists will be able to monitor what’s happening in the animal’s brain.
Helen Schwerdt, a bioengineer whose lab builds tools to measure brain activity, plans to place up to 100 tiny sensors in the brain of each animal long before they develop symptoms of Parkinsons. Those sensors will monitor levels of dopamine, the chemical messenger that’s lacking in Parkinson’s.
“This is the first time that we can actually look at these dopamine signals and see what happens over the course of months and even a year,” Schwerdt says.
When a monkey anticipates getting a smoothie, the sensors should reveal a burst of dopamine signals coming from the brain circuit that controls movement.
If that happens, it would confirm Strick’s hypothesis, and provide a potential new target in the brain for Parkinson’s treatments. The hope is that by using electrical stimulation or a drug aimed at this target, the team can not only switch on the circuit that allows movement, but keep it on.
Click here to read the full article on NPR.
